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Abstract 
 
Purpose: Patients with primary antibody deficiency report poorer quality of life and higher rates of 
anxiety and depression than the general population. Cognitive-behavioural therapy has been shown to 
be a valuable treatment for patients with other long-term physical health conditions, improving 
wellbeing and enabling them to manage their symptoms more effectively. The aim of this project was 
to establish the feasibility and effectiveness of providing cognitive-behavioural based therapy to 
patients with primary antibody deficiency. 
Methods: Forty-four patients completed a course of psychological therapy. Participants completed a 
series of self-report measures examining psychological and physical health, and service usage, prior to 
starting treatment and following their final session. They also provided feedback on their experience of 
treatment.  
Results: Patients showed improvements in anxiety, depression, insomnia and fatigue. There was a high 
level of acceptability of the service and the potential for long-term cost savings to the NHS.  
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Conclusion: Psychological therapy based on the cognitive-behavioural model of treatment appears to 
be a valuable treatment for patients with primary antibody deficiency and comorbid mental health 
difficulties.  
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Introduction 
 
Research and anecdotal evidence suggest a bi-directional relationship between mental and physical 
health. Individuals with chronic illnesses are more likely to experience mental health problems when 
compared to the general population1. The National Institute for Clinical Excellence2 found that adults 
with a chronic physical health problem are around two to three times more likely to experience 
depression than those with good physical health, and that a physical health problem can be both a 
predisposing and a maintenance factor for low mood. The Department of Health’s Long-term 
Conditions Positive Practice Guide3 suggests that depression and/or anxiety can increase individual 
distress, the perceived severity of physical symptoms, use of other healthcare services and overall 
physical healthcare costs.  
 
There is growing evidence to suggest that treating psychological factors in patients with physical health 
problems can improve patient quality of life and provide cost savings to the NHS (for example, through 
better understanding of and concordance in treatment, and appropriate use of medication and 
resources). The King’s Fund reported that in patients with long-term conditions, comorbid mental 
health problem generate at least a 45% increase in total healthcare costs, and highlighted that better 
integrated physical and psychological services in the UK will produce cost savings as well as better 
care1. The cost benefits, as well as the quality outcomes associated with patient-centred (as opposed to 
condition-centred) care have been stressed by many leading professionals and professional bodies 1,3,4,5.  
 
In terms of the model or type of psychological treatment, the best evidence for effectiveness in physical 
health settings is for cognitive behaviour therapy (CBT). NICE2 therefore recommend that treating 
depression and other psychological factors in individuals with a physical health problem using CBT, 
has the potential to improve both quality of life and life expectancy2. CBT has been shown to improve 
psychological well-being within a number of different physical health conditions, including Chronic 
Fatigue Syndrome6-7, Chronic Pain8, Diabetes9 and Chronic Obstructive Pulmonary Disease10. 
 
Primary Antibody Deficiency (PAD) is a chronic physical health condition with a minimal prevalence 
estimated at 2.1/100,000 of the UK population11. Characterised by recurrent and persistent infections at 
multiple sites, the initial diagnosis can occur at any point in the lifespan and there is often a delay from 
first presentation of illness12. Medically, PAD is managed using a combination of replacement 
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immunoglobulin therapy and prophylactic antibiotics. Immunoglobulin replacement can be 
administered by either intravenous or subcutaneous Immunoglobulin Therapy, ranging from weekly to 
once a month, which has been shown to have beneficial effects for patients’ physical health13. 
However, despite appropriate treatment, recent research suggests that PAD can negatively affect a 
patient’s quality of life, with approximately 40% of patients at risk for high levels of physical disability 
and psychological distress14.  
 
Although empirical evidence is scarce, the psychological impact of having a chronic health condition 
can be far reaching and is clearly evident in PAD14-16. Booker and colleagues examined health-related 
quality of life and adjustment to illness in PAD and found that 23.7% of patients reported moderate to 
severe levels of depression and 27% reached ‘caseness’ for anxiety14. The researchers suggest that 
many of the factors (such as fear of breathlessness, negative attitude to diagnostic delay, concerns over 
the future impact of illness, fatigue, global stress and low levels of palliative coping strategies) which 
influenced quality of life (defined as poor physical functioning and high levels of depression and 
somatic symptoms) would be amenable to change through the use of psychological techniques and 
support, particularly a cognitive-behavioural based treatment. Other research and patient groups have 
also highlighted the need for the provision of psychological therapy as part of the standard care 
package for people with PAD14-17. Therefore, the aim of this project was to establish the feasibility and 
effectiveness of providing cognitive-behavioural based therapy to patients with PAD. We hypothesised 
that the CBT would provide similar benefits for patients with PAD as those with other long-term 
physical health conditions.   
 
 
  
5 
 
	
Methods 
 
Design 
A case series design was used to investigate the impact of psychological therapy for patients with PAD.  
 
Participants 
Patients attending the Royal Free Hospital Clinical Immunology Department, prescribed 
Immunoglobulin Replacement Therapy for PAD and identified through the screening questionnaire as 
experiencing anxiety, depression, insomnia or fatigue,  were invited to attend for an initial assessment 
with a Clinical Psychologist. In addition, patients who had undergone transition from Paediatric 
Services were offered an assessment, as transition can be a time of confusion and distress18 and poor 
transition can lead to poor outcomes for both physical and mental health19. . Informed consent was 
obtained from all individual participants in the study.  
 
Measures 
We used the Primary Immunodeficiency Quality of Life Index (PIQoLI)14 for the identification of 
suitable patients for treatment and to evaluate outcome following treatment. The PIQoLI is an 
aggregate measure that uses abbreviated and/or standardised short versions of the validated measures 
used in Booker and colleagues quality of life survey14. Strong correlations between the short form and 
standard versions of the questionnaire have been shown in patients wtih PAD20.It asks patients to self-
report on different aspects of their life known to influence quality of life. Seven subscale scores 
(Perceived Illness Severity, Fatigue, Fear of Breathlessness, Worry about Illness, Depression, Anxiety 
and Insomnia) are gained. Indicators of referral for psychological treatment include a Depression score 
of 7+, an Anxiety score of 15+, a Fatigue score of 12+, or an Insomnia score of 15+.  
The Functional Assessment of Chronic Illness Scales – Fatigue (FACIT-F)21 is a 13-item questionnaire 
where patients rate, on a five-point Likert-scale, their fatigue over the last seven days. It has been 
shown to be a reliable and valid measure of fatigue across a number of different clinical populations, 
has good test-retest reliability (r = 0.90) and internal consistency (Cronbach’s alpha range = 0.93-0.95), 
demonstrates good convergent and discriminant validity, and has been shown to detect clinically 
significant change over time21-22.  
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The Hospital Anxiety and Depression Scale (HADS)23 is a 14-item self-report measure specifically 
designed for use in outpatient medical settings and often used in health psychology research. 
Participants indicate how they have felt over the past week on a four-point Likert scale and scores are 
summed to generate two subscales (Anxiety & Depression). It has been shown to be a valid, reliable 
and acceptable measure24.  
 
The Inventory of Health Status Part II V3 (IHS)25 is a 64-item self-report questionnaire designed to 
measure somatic symptoms. Participants are asked to indicate the occurrence of a variety of different 
physical health complaints over the last month or two.  
 
The Perceived Stress Scale (PSS)26 is a measure of the degree to which situations in one’s life are 
appraised as stressful. It asks participants to rate, on a five-point Likert scale, their feelings and 
thoughts during the last month. It has shown adequate test-retest reliability and internal consistency 
(Cronbach’s alphas = 0.84-0.86), and good concurrent, predictive and discriminant validity26.   
 
The Functional Assessment of Chronic Illness Scales – Treatment Satisfaction – General (FACIT-TS-
G)27 is an eight-item questionnaire where patients rate their satisfaction with treatment. It has been 
shown to be a reliable and valid measure of satisfaction with treatment across different clinical 
populations. The two subscales (Treatment Satisfaction and Recommendation) have demonstrated good 
internal consistency and convergent validity27. Higher scores indicate greater levels of satisfaction.  
 
Self-Designed Cost-effectiveness Questionnaire 
Patients were asked about the number of general practitioner (GP), hospital and emergency 
appointments (including length of stay), contacts with the Immunology Department for advice or 
information, courses of antibiotics, days off work/education due to ill health and medical appointments, 
and any inability to fulfil household tasks over the three months prior to starting psychological therapy 
and the three months preceding the final appointment. They were also asked about the number of hours 
they spent outside of their home in the week prior to the start and end of treatment as an indicator of 
general activity.  
 
Procedure 
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Recruitment was through a convenience sample of patients attending Immunology clinics. Following 
initial assessment an individualised formulation and treatment plan was developed and, if thought to be 
beneficial, patients were then offered a short course of Cognitive-Behavioural based therapy to address 
the difficulties identified.  
 
As part of treatment patients were asked to complete measures of somatic symptoms, global stress, 
mood, anxiety, insomnia, fatigue, impact on daily life and medical service usage at the start and end of 
treatment. A measure of patient satisfaction was completed at the end of therapy. Demographic data 
and information about the number of sessions attended were gathered from clinical notes.  
 
The study was granted ethical approval from Bromley Research Ethics Committee (Ref: 11/LO/1126). 
 
Statistical Analysis 
Distribution of data was assessed for normality. For the parametric data, paired sample t-tests were 
used to examine change following treatment. For the non-parametric data, Wilcoxon signed ranks tests 
were used. We used an alpha value of 0.004 for all statistical tests. Acceptability was investigated by 
examining rates of drop-out and mean scores on the FACIT-TS-G. Healthcare usage was investigated 
by examining patient reports of the total number of GP and hospital appointments, emergency visits 
and inpatients admissions in the three months prior to the first and last appointment for treatment.  
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Results 
 
Participant Demographics 
Fifty-five patients consented to take part in the project and attended a psychological assessment. The 
group had a mean age of 47.5 years (SD = 16.6). Thirty-three percent (N = 18) were male and 67% (N 
= 37) were female. They had a variety of diagnoses: Common variable immunodeficiency (N = 33), 
IgG subclass deficiency (N = 3), other hypogammaglobulinemia (N = 6), IgA deficiency (N = 2), 
Specific Antibody Deficiency (N = 3), X-linked agammaglobulinaemia (N = 3), Good Syndrome (N = 
1), MBL deficiency (N = 1), Unclassified immunodeficiency (N = 2), and Wiskott-Aldrich Syndrome 
(N = 1). Forty-five patients classified themselves as White – British, two as White – Other, four as 
Asian, Asian British Indian or Asian British – Pakistani, three did not state their ethnicity,  and one as 
Other Ethnicity. 
Uptake and treatment package 
Figure 1 details the participant flow through the study. Following assessment, 48 patients (87%) were 
offered a package of psychological therapy. Four were discharged after assessment as it was felt by 
both therapist and patient that they were managing well, and three were referred on for more suitable 
treatment with their local psychology service. One patient declined treatment without giving a reason. 
One patient remains in treatment and is therefore excluded from all further analysis. Forty-one patients 
completed a course of treatment with sessions terminated by mutual agreement between therapist and 
patient, and 5 terminated treatment early, of their own accord, partially completing the course of 
therapy (e.g., dropped out of treatment).  
 
INSERT FIGURE 1 ABOUT HERE 
 
Patients who completed therapy attended a median of six sessions (Range = 3-24 sessions), and those 
who partially completed attended a median of four sessions (Range = 3-6 sessions). There was a higher 
percentage of men in the partial completers group compared with those who completed a full course of 
treatment (table 1). Partial completers also appeared to be younger, have lower levels of somatic 
symptoms and perceived stress at baseline than completers. Baseline scores of anxiety, depression and 
fatigue were at similar levels.  
 
INSERT TABLE 1 ABOUT HERE 
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The remit of psychological therapy was broad. Patients were treated with cognitive-behavioural based 
therapy. CBT is a time limited, systematic, evidence based therapeutic approach, recommended by 
NICE and delivered by qualified mental health professionals. Taking into account the individual needs 
of each patient, treatment aims included developing skills to improve mood and sleep, to reduce stress, 
anxiety or insomnia, teaching individuals how to monitor and respond to symptoms adaptively, and/or 
providing a space for patients to reflect on the impact the illness had had on their lives and 
relationships. 
 
Effectiveness 
 Following treatment patients who completed a course of treatment reported significant 
improvements in mood, anxiety fatigue and insomnia (table 2). Despite a slight increase in days off 
work due to ill health, they also reported a greater number of hours spent outside the house per week.  
 
INSERT TABLE 2 ABOUT HERE 
 
Healthcare usage 
Figure 2 details the changes in antibiotic medication and medical service usage over the three months 
prior to the first and last psychology appointment for the whole cohort who completed a full course of 
treatment. Patients showed an increase in courses of prophylactic antibiotics, GP appointments and 
hospital emergency (A&E) visits, and a reduction in outpatient (OP) appointments and in-patient (IP) 
admissions. The number of courses of breakthrough antibiotics remained stable. 
 
INSERT FIGURE 2 ABOUT HERE 
 
Acceptability  
Patients reported high satisfaction with the service: Mean FACIT Treatment Satisfaction Scale (N = 
40) = 91.7% (SD = 15.6), Mean FACIT Treatment Recommendation Scale (N = 39) = 98.1% (SD = 
8.9). Thirty-nine (out of 40) patients said that they would recommend the treatment to someone with 
their condition (1 maybe) and thirty-seven patients would choose the treatment again (2 maybe, 1 
missing data). This acceptability is also supported by the relatively low level of drop-out from the 
service (only five patients did not complete the course of therapy that was offered to them). 
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Discussion 
 
Adults with PAD have been shown to have poor quality of life and higher rates of anxiety and 
depression when compared to the general population. The effectiveness and acceptability of 
psychological treatments, particularly cognitive-behavioural therapy, is well established for mental 
health difficulties and some physical health conditions. However to date no-one has examined the 
utility of using this treatment model to improve the mental health and quality of life for patients with 
PAD. Therefore, this study examined the effectiveness, potential cost-effectiveness and acceptability of 
providing cognitive-behavioural based treatment within this population. As hypothesised, and in line 
with research on the impact of cognitive-behavioural therapy for patients with other long-term medical 
conditions, improvements in mood, anxiety, sleep and energy levels were found for patients with PAD 
who completed a full course of psychological therapy. Patients who completed treatment also reported 
an improvement in their activities of daily living (e.g., greater time spent outside of the house, and a 
trend towards less time off work and less days unable to fulfil household tasks) and a positive change 
in their medication and medical service usage.  
 
There was also a high level of acceptability and satisfaction with the model of treatment. All treatment 
completers were satisfied with their treatment decision, would do it again and recommend to others. 
Attrition rates were below the average of patients who receive cognitive-behavioural therapy for other 
conditions. The total attrition rate in this study was 12%, with a within treatment attrition rate of 
10.2%, compared with population averages of 36% and 26.2% respectively28.  
 
As with other long-term medical conditions, it is clear that there is a substantial group of patients with 
PADS who experience associated psychological difficulties, and for whom psychological intervention 
is very effective. The treatment works by reducing fear and uncertainty about the condition, helping 
patients to develop strategies to lessen its impact on their life and future, and increasing the ability to 
self-manage symptoms. Not surprisingly this has an impact on quality of life and lifestyle benefits such 
as return to work and increased social engagement. There is also evidence of more appropriate use of 
services (e.g., increase in GP appointments, but a reduction in hospital outpatient appointments and 
inpatient stays). All these changes have associated cost benefits although some sit outside the health 
service (e.g., tax income, reduced state benefits after return to work). Further in depth research is 
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required to fully understand the cost implications of this treatment, in particular whether the costs of 
providing the therapy are offset by more appropriate use of services. 
 
The study has identified a potentially positive addition to medical treatment in improving quality of life 
for patients with PADS. However, prudence should be given to the data with regards to the 
heterogeneity of the population, presenting mental health needs and treatment aims. Further research is 
needed to better understand the outcomes and factors that impact this for differing patient 
presentations.  
 
Caution also needs to be taken when interpreting the results due to the relatively small sample size and 
high level of analysis conducted. Future studies, with more power to conduct median analyses, are 
needed in order to establish the role that other factors, particularly current health status, play in 
treatment and outcome. As subjects were not randomised to intervention, a formal intention to treat 
analysis was not undertaken. When all participants were analysed only the FACIT-fatigue had 
statistical significance (data not shown, non-parametric statistical methods used due to skewed data 
distribution). However, given the overall sample size we would expect that failure to complete therapy 
would alter the likelihood of successful outcome. Further research should consider the use of a control 
group to ensure that the improvement can be attributed to CBT rather than non-specific treatment 
benefits. It will also be important to examine the longer-term outcome of the patients in this population 
to establish whether the effects of therapy continue over time. Finally, as the research took place within 
a single specialist service, with only one Clinical Psychologist working with the patient group, it will 
be important to examine the generalisability of these findings to the wider population of patients with 
Primary and Secondary Immunodeficiencies.  
 
In conclusion, with both patients and professionals noting the importance of integrating medical and 
psychological treatments17, 29 it should be possible to improve Immunology services by  providing 
psychological support alongside medical and nursing interventions.  
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Tables 
 
Table 1: Differences between completers and partial-completers 
 Completers Partial-completers 
Gender 30 Female (73%) 
11 Male (27%) 
3 Female (60%) 
2 Male (40%) 
Age 49.8 (16.3) 38.4 (16.2) 
Baseline HADS Anxiety 9.1 (4.5) 8.6 (5.5) 
Baseline HADS Depression 6.5 (5.0) 6.0 (5.7) 
Baseline FACIT Fatigue 25.4 (13.8) 27.2 (10.8) 
Baseline Somatic Symptoms 19.7 (9.1) 13.0 (6.4)  
Baseline Perceived Stress 21.2 (7.9) 15.8 (10.5) 
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Table 2: Changes following treatment for patients who completed a course of psychological therapy 
 N Baseline Mean 
(Standard 
Deviation) 
End of 
Treatment 
Mean (Standard 
Deviation) 
t  p Value 
HADS – Anxiety 39 9.1 (4.5) 7.2 (4.7) 3.308  .002 
HADS – Depression 39 6.5 (5.0) 4.6 (4.2) 3.117  .003 
FACIT Fatigue a 36 24.8 (13.6) 29.2 (13.2) -3.276  .002 
PIQoLI – Anxiety  38 13.6 (4.4) 12.3 (4.9) 2.081  .044 n.s. 
PIQoLI – Depression 39 4.7 (3.3) 3.4 (3.3) 3.032  .004 
PIQoLI – Fatigue 39 9.5 (4.7) 7.2 (5.2) 3.565  .001 
PIQoLI – Insomnia 36 13.1 (6.6) 9.3 (7.7) 3.804  .001 
      
a Higher score = lower fatigue 
 N Baseline  
Median 
End of 
Treatment  
Median 
Z  p Value 
Hours outside home 
per week 
39 25.0 35.3 -2.910 .004  
Days off work 
medical 
appointments b  
17 c 1.5 1.5 -0.552 .581 n.s. 
Days off work ill 
health b 
17 c 0.0 1.0 -2.346 .019 n.s. 
Days unable to 
complete household 
tasks b 
39 2.5 2.0 -1.029 .303 n.s. 
b In the three months prior to appointment. c data only available for those in employment at 
commencement of treatment. 
N.B., Data only analysed if participants had completed both the pre- and post-treatment measures. 
Missing data accounts for the reduced N in some analysis. 
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Figures 
Figure 1: Participant flow through the study 
 
 
 
 
 
 
 
 
 
Figure 2: Total medication and medical service usage for patients (N = 40) who completed a course of 
psychological therapy for the three months prior to first and last psychology session.  
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